Vaxcyte, Inc. (PCVX) — Analyst outlook / Analyst consensus target is. Based on 11 analyst ratings, the consensus is bullish — 11 Buy.
The consensus price target is $83.00 (low: $77.00, high: $89.00), representing an upside of 32.2% from the current price $62.76.
Analysts estimate Earnings Per Share (EPS) of $-3.91 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.80 vs est $-3.91 (beat +2.8%). 2025: actual $-5.63 vs est $-5.44 (missed -3.5%). Analyst accuracy: 97%.
PCVX Stock — 12-Month Price Forecast
$83.00
▲ +32.25% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Vaxcyte, Inc., the average price target is $83.00, with a high forecast of $89.00, and a low forecast of $77.00.
The average price target represents a +32.25% change from the last price of $62.76.
Highest Price Target
$89.00
Average Price Target
$83.00
Lowest Price Target
$77.00
PCVX Analyst Ratings
Buy
Based on 11 analysts giving stock ratings to Vaxcyte, Inc. in the past 3 months
EPS Estimates — PCVX
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.80
vs Est –$3.91
▲ 2.9% off
2025
Actual –$5.63
vs Est –$5.44
▼ 3.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — PCVX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
